An immunotherapy kept multiple myeloma at bay for over 80 percent of patients in a three-year clinical trial, and the FDA ...

An Aussie social media influencer was rushed to hospital after she endured a severe allergic reaction to getting her lip ...

Zycubo received breakthrough therapy, fast track, rare paediatric disease and orphan drug designations from the FDA.

A significantly higher proportion of 4- to 7-year-olds with peanut allergy using the Viaskin Peanut patch were deemed ...

Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track program ...

Peanut oral immunotherapy is generally safe, but rare, severe immediate allergic reactions may emerge months into treatment, a real-world French study shows.

AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin ...

An oncology pharmacist shares how a treatment takes a different approach to treating chronic graft-versus-host disease (GVHD) ...

Grandmother decided to learn the game to get rid of the stress of her grandson's cancer treatment. However, she later made it ...

Learn more about peanut oral immunotherapy (OIT) and how lowering the treatment dose could help children with peanut ...

The FDA approved copper histidinate (Zycubo) as the first treatment for Menkes disease in pediatric patients, the agency ...

The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...